# OnCo record adenosine-and-ido (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/adenosine-and-ido/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "adenosine-and-ido" ;
  schema:name "Adenosine and IDO: two separate routes that can restrain immune responses"@en ;
  schema:description "Adenosine can signal immune cells to reduce activity; the IDO1 enzyme starts a separate route that breaks down tryptophan, an amino acid. Finding their components in a tumour does not prove immune suppression or drug benefit. An IDO1 blocker added to pembrolizumab did not improve melanoma outcomes in a phase 3 trial."@en ;
  schema:url <https://onco.cc/terms/adenosine-and-ido/> ;
  schema:dateModified "2026-11-10"^^xsd:date ;
  schema:citation <https://doi.org/10.1084/jem.20062512>, <https://doi.org/10.1073/pnas.0605251103>, <https://doi.org/10.1172/jci21583>, <https://doi.org/10.1152/ajpheart.1990.258.4.h1232>, <https://doi.org/10.1016/s1470-2045(19)30274-8>, <https://www.uniprot.org/uniprotkb/P14902/entry> ;
  onco:targets <https://onco.cc/targets/ido1/>, <https://onco.cc/targets/entpd1/>, <https://onco.cc/targets/cd73-adenosine/>, <https://onco.cc/targets/adora2a/> ;
  onco:drugs <https://onco.cc/drugs/epacadostat/> ;
  onco:pathways <https://onco.cc/pathways/tumor-microenvironment/> ;
  onco:terms <https://onco.cc/terms/immune-checkpoint/>, <https://onco.cc/terms/inflammation/> .
